Physician profile
Heather E Gunnarson
NPI 1578587739
$3,269.33
in general payments reported to CMS, 2019-2025
33 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $275 · 2021: $781 · 2022: $532 · 2023: $220 · 2024: $415 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.00 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $273.54 | 2021-2025 | |
| Aspira Women'S Health INC | $204.75 | 2021-2024 | Ova1 |
| Astellas Pharma US INC | $184.92 | 2019-2024 | Veozah |
| Allergan, INC. | $176.86 | 2019-2021 | |
| Daiichi Sankyo INC. | $153.00 | 2020-2022 | |
| Shield Therapeutics INC | $149.19 | 2022-2025 | |
| Hologic Sales and Service, LLC | $133.77 | 2022-2025 | Aptima |
| Pfizer INC. | $133.64 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.09 | 2019-2022 | |
| Biogen, INC. | $99.30 | 2024-2025 | Zurzuvae |
| Channel Medsystems, INC. | $85.93 | 2022-2023 | |
| Amgen INC. | $84.51 | 2021-2025 | Evenity, Prolia, Prolia |
| Exeltis, USA INC. | $83.72 | 2019-2021 | |
| Avion Pharmaceuticals | $81.64 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $74.13 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $72.29 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $68.65 | 2019-2020 | |
| Coopersurgical, INC. | $64.97 | 2019-2025 | Insorb |
| Lupin INC. | $56.04 | 2019-2020 | |
| Therapeuticsmd, INC. | $54.01 | 2019-2020 | |
| Ethicon US, LLC | $47.75 | 2019-2025 | Evarrest, Stratafix |
| Vertical Pharmaceuticals, LLC | $47.61 | 2019 | |
| Evofem Biosciences, INC. | $32.90 | 2021 | |
| Exact Sciences Corporation | $31.76 | 2023 | Cologuard Collection Kit |
| Mission Pharmacal Company | $31.39 | 2019 | |
| Amag Pharmaceuticals, INC. | $30.53 | 2019 | |
| Biom'Up Sa | $28.30 | 2019 | |
| Merck Sharp & Dohme LLC | $27.63 | 2019 | |
| Lilly USA, LLC | $25.55 | 2019-2021 | |
| Organon LLC | $22.41 | 2022 | |
| Millicent US INC | $13.85 | 2024 | Intrarosa, Femring |
| Minerva Surgical, INC | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gunnarson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.